Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study

BACKGROUND: Pirfenidone and nintedanib are antifibrotic therapies which slow disease progression in idiopathic pulmonary fibrosis (IPF), an irreversible, progressive lung disease with poor prognosis. We compared adherence, persistence, and healthcare costs between patients initiating one of the two...

Descripción completa

Detalles Bibliográficos
Autores principales: Corral, Mitra, DeYoung, Kathryn, Kong, Amanda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353678/
https://www.ncbi.nlm.nih.gov/pubmed/32652979
http://dx.doi.org/10.1186/s12890-020-01224-5

Ejemplares similares

Ejemplares similares